Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a ...

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

GPCR drug developer Septerna plans to raise about $157 million in net proceeds from its proposed initial public offering, ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

The gross proceeds from the offering are expected to be $288.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

AbbVie and Sosei Heptares will initially focus on developing up to three GPCR-modulating small-molecule drugs to the point at which they are ready to start clinical trials in humans, whereupon ...

In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – ...